PassPort Technologies, Inc.

SAN DIEGO, Feb. 23, 2024 /PRNewswire/ -- PassPort Technologies, Inc. (PPTI), based in San Diego, initiated a US Phase 1 clinical study of Zolmitriptan PassPort® utilizing its proprietary transdermal microporation system, PassPort® platform technology. The study objectives are to evaluate the safety of PassPort® system and pharmacokinetics to anticipate a faster onset of action compared to zolmitriptan oral tablet. Zolmitriptan, marketed under the brand name ZOMIG®, is an FDA-approved prescription medication used for treating migraine symptoms. "We believe our Zolmitriptan PassPort® provides significant advantages of faster onset of action and higher efficacy for migraine patients with severe nausea and patients who are non-responsive to oral triptans" said President and CEO Tomoyuki Fujisawa. An open-label, randomized, crossover study consisting of 32 healthy volunteers is testing the safety, tolerability, and pharmacokinetics of Zolmitriptan PassPort® with 3 different doses, administered to the subject's upper arm, compared to oral administration of zolmitriptan. Additionally, the study will evaluate the transdermal administration of a single dose at alternative sites, the subject's abdomen and upper thigh. Interim pharmacokinetic data will be available to the public in March 2024. Continue Reading About PassPort Technologies, Inc. As a cutting-edge biotechnology entity, PPTI is committed to the swift development and patient delivery of exceptional pharmaceuticals through the PassPort® system. The company aims to constantly develop technologies that serve the pharmaceutical industry and broader life sciences sectors. PPTI's mission is to advance global health outcomes. Further details can be found at . PassPort® platform technology will be able to provide faster onset of action and higher efficacy benefiting severe migraine patients. Post this About PassPort® Technology The PassPort® System integrates patented painless skin microporation and dry patch formulation technologies to regulate drug delivery through the micropores created in the skin. This innovative system enables transdermal delivery of not only small molecules but also peptides, proteins, and RNAs for therapeutics and infection vaccines. Forward-Looking Statement Except for historical information, all the statements, expectations, and assumptions contained in this Press Release are forward-looking statements. Actual results may differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the early phase of the clinical trial; risks associated with the drug development process; competition; reliance on key personnel; and other risks described in other PassPort Technologies, Inc. press releases and presentations. SOURCE PassPort Technologies, Inc.

Arcturus's mRNA medicines and vaccines and lipid-mediated drug delivery systems in combination with PassPort's innovative transdermal drug delivery system. SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- PassPort Technologies, Inc. (PPTI), led by President and CEO Tomoyuki Fujisawa in California, USA is pleased to announce the initiation of a collaborative research endeavor with Arcturus Therapeutics (ARCT). This research collaboration is focused on evaluating innovative mRNA formulations and transdermal delivery mechanisms for vaccines and therapeutics. Continue Reading The research collaboration will leverage ARCT's expertise in mRNA design and proprietary LUNAR® platform technologies, alongside PPTI's groundbreaking PassPort® transdermal drug delivery technology. PPTI will utilize its unique platform technology and extensive knowledge in transdermal biologics and oligonucleotides delivery. ARCT will supply select mRNA and LUNAR® formulations, which PPTI will subsequently adapt to the PassPort® system. PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery Post this About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive™, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit . In addition, please connect with us on Twitter and LinkedIn. About PassPort Technologies, Inc. As a cutting-edge biotechnology entity, PPTI is committed to the swift development and patient delivery of exceptional pharmaceuticals through the PassPort system. The company aims to constantly develop technologies that serve not only the pharmaceutical industry but also broader life sciences sectors. PPTI's mission is to advance global health outcomes. Further details can be found at . About PassPort® Technology The PassPort® System integrates microporation technology to painlessly form micropores in the skin seamlessly and a patch formulation technology that regulates drug delivery through these micropores. This innovative system now enables transdermal delivery of biologics and oligonucleotides, which were previously limited to injections and infusions. ■For inquiries regarding this matter, please contact: E-mail: [email protected] URL: SOURCE PassPort Technologies, Inc.